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Background: Intracellular parasites, such as T. gondii, present a plurality of antigens because of the complexity of its
life cycle. Compound DNA vaccines bring a new approach and hope for the treatment of toxoplasmosis. In this
study, a DNA vaccine encoding two major surface antigens SAG1, SAG3 from T. gondii, with A2/B subunit of cholera
toxin as a genetic adjuvant was constructed.
Methods: BALB/c mice were immunized intramuscularly with PBS, pcDNA3.1, pSAG1, pSAG1/SAG3 and pSAG1/
SAG3-CTXA2/B three times separately. Immunized mice were tested for IgG antibody and IFN-γ and IL-4 production
by ELISA. The proliferation of T cells was measured by DNA synthesis assay and the lymphocyte subsets of spleen
cells by flow cytometry. All the immunized mice were challenged with 103 highly virulent RH tachyzoites of
Toxoplasma gondii intraperitoneally and the survival times were recorded.
Results: An enhanced production of IgG antibodies, antigen-specific lymphocyte proliferation and IFN-γ production
from splenic cells were induced in mice immunized with pSAG1/SAG3 compared to mice immunized with pSAG1
(P<0.05). Introduction of CTXA2/B further enhanced the Th1 cell-mediated immunity with higher levels of IFN-γ,
lymphocyte proliferation activity and percentage of CD8+ T-cells. When challenged with lethal doses of T. gondii (1×103),
all control mice (PBS and empty plasmid group) died within 6 days. Mice immunized with pSAG1 died within 8 days.
While 20% and 40% survival rate were achieved from mice immunized with pSAG1/SAG3 and pSAG1/SAG3-CTXA2/B.
Conclusions: This study indicates the compound DNA vaccine encoding T. gondii antigens SAG1, SAG3 with CTXA2/B
gene was a promising DNA vaccine candidate against toxoplasmosis, which could effectively enhance the humoral and
cellular immune response and prolong survival time in vaccinated mice.
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Toxoplasma gondii is a single-cell obligate intracellular
protozoan, which is widely prevalent all over the world.
Prevalence of T. gondii infection increased by 7% during
the past ten years in China [1]. This parasite is of major
medical importance, being a cause of congenital disease
and abortion [2]. In immunocompromised patients, such
as those with cancer or AIDS, the disease can be fatal* Correspondence: conghua@sdu.edu.cn
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reproduction in any medium, provided the or[3,4]. Development of an effective vaccine is an attractive
way to prevent this disease.
In recent years, T. gondii vaccines have made great
progress from the earlier mutant strains to the latest
DNA vaccine [5-9]. Especially compound polyvalent
DNA vaccines bring about a new approach and hope for
T. gondii. Because complex intracellular parasites, such
as T. gondii, present a plurality of antigens and as the
antigen presentation capability varies widely among dif-
ferent individuals, immunization with a vaccine that in-
cludes a broad array of antigens is likely to be more
efficacious than a single antigen.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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host immune response. The tachyzoite surface is domi-
nated by SAG1, SAG2A, SAG3, SRS1, SRS2, and SRS3
[10]. Examples of immunization experiments with T.
gondii DNA encoding SAG antigens, alone or in com-
bination with other antigens have already been reported
[11-13]. SAG1 and SAG3 share an overall similar fold-
ing, which was shown to participate in the cellular inva-
sion by the parasite [14,15]. The SAG1 gene, encoding
T. gondii P30 protein and accounting for 5% of all pro-
teins in the tachyzoite, is the first tachyzoite antigen to
be cloned and sequenced, which enables invasion of host
cells by binding to cellular receptors [16]. This protein
links the parasite and host cell receptor, which favours
parasite invasion of host cells [17]. SAG3 is the first
glycoaminoglycan-binding protein associated with Toxo-
plasma, and SAG3–heparan sulfate proteoglycans (HSPGs)
interactions are involved in the parasite attachment to tar-
get cells [18]. A previous study clearly demonstrated that
SAG3 is important for the parasite adhesion to host cells
[19], which was considered as one member of the receptors
system of T. gondii that act as ligands mediating host cell
recognition and attachment. Although SAG3 is very similar
to SAG1 in structure and function, few studies have been
performed with SAG3.
In this study, we constructed a DNA vaccine express-
ing two major surface antigens SAG1, SAG3 from T.
gondii, with the A2/B subunit of cholera toxin as a gen-
etic adjuvant. The immunity induced by this DNA vac-
cine in BALB/c mice and the protection afforded against
challenge with the highly virulent RH strain of T. gondii
is evaluated.
Methods
Parasites and soluble tachyzoite antigens
The tachyzoites of the highly virulent RH strain of T.
gondii were stored in liquid nitrogen in our laboratory.
The parasites were maintained by serial intraperitoneal
passage in BALB/c mice. The tachyzoites were harvested
from the peritoneal fluid of mice after 72 h, and used for
genomic DNA extraction, the vaccine challenge infec-
tion study and soluble tachyzoites antigens extraction.
The peritoneal fluid was washed by 0.01M phosphate
buffered saline (PBS) three times in a low speed centrifu-
gation and disrupted using an ultrasonic disintegrator,
followed by freezing and thawing (six cycles), and then
centrifuged at 1500×g for 15 min. The supernatant
containing soluble tachyzoites antigens (STAg) was kept
at −20°C until further use.
Plasmids construction
Three pairs of primers were designed and synthesized
according to the published gene sequence of T. gondii
(RH strain) and the A2/B subunit of cholera toxin.Restriction endonuclease sites were added at the 50 ends
of sense and antisense strands of the primers, respect-
ively, to allow SAG1 gene, SAG3 gene and CTXA2/B
gene orientation and to ensure the precision of the
opening reading frame.
SAG1 primer: forward 50-CGGAATTCATGACGGAG
AACCACTTCACTC-30, reverse 50-ATGGATCCCGCGA
CACAAGCTGCGATAG-30; SAG3 primers: forward ’-
GGATC GGA TCC ATGCAGCTGTGGCGGCGCAGA
GC-30, reverse 50-TGATCGGTACCTTTCTGTTCCAGC
TTGACTTTCC- 30; CTXA2/B primers: forward 5
0- CG
GGT ACC AGT AAT ACT TGC GA- 30, reverse 50- AC
AAGCTTTTA ATT TGC CAT AC-30 .
The compound gene was obtained by T-A cloning
(TaKaRa, Dalian) and introduced into the eukaryotic ex-
pression plasmid pcDNA3.1 (−) vector by EcoR I/ BamH I,
EcoR I/Kpn I or EcoR I/Hind III cloning sites separately.
The construction of DNA vaccines was shown in Figure 1.
Escherichia coli DH5α cells were transformed with the li-
gation mixture by calcium chloride. The recombinant plas-
mids pSAG1, pSAG1/SAG3 and pSAG1/SAG3-CTXA2/B
with the correct insert orientation was detected by restric-
tion enzymes analysis, PCR and then purified by a column
chromatography kit (Omega, USA) and sequenced (Bioasia,
Shanghai).
Expression of compound gene in vitro
The recombinant eukaryotic expression plasmids pSAG1,
pSAG1/SAG3 and pSAG1/SAG3-CTXA2/B were trans-
fected into HeLa cells by liposomes (LipofectAMINE™
2000, Invitrogen) and stable strains of transfectants were
obtained after being screened by G418 (Gibco, BRL). The
genes that input in the plasmid pcDNA3.1 were verified to
have the capability to transcript in vitro by RT-PCR.
Immunization of BALB/c mice
SPF BALB/c female mice (6–8 weeks old) were used in
all the immunization and parasite challenge experi-
ments. They were purchased from Shandong University
Laboratory Animal Center and maintained under stand-
ard conventional conditions. All studies were conducted
with approval from the Institutional Animal Care and
Use Committee at the University of Shandong.
Large scale recombinant plasmid DNA was prepared
by the alkaline lysis method. Plasmids were diluted and
suspended in sterile phosphate buffered saline (PBS) to a
final concentration of 1 μg/μl. BALB/c mice were ran-
domly divided into five groups (20 mice/each group).
Three experimental groups of mice were injected with
100 μl of 1 μg/μl plasmid pSAG1, pSAG1/SAG3 and
pSAG1/SAG3-CTXA2/B separately in the quadriceps
muscle. Two control groups received 100 μg of empty vec-
tor pcDNA3.1 or 100 μl PBS (Phosphate buffered saline).
Booster immunizations were administered twice at 2 week
Figure 1 The schematic diagram of the construction of DNA vaccines. SAG1 gene, SAG3 gene of T. gondii and CTXA2/B gene of cholera toxin
were introduced into the eukaryotic expression plasmid pcDNA3.1 (−) vector by EcoR I / BamH I, EcoR I / Kpn I or EcoR I / Hind III cloning sites.
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the tail vein serum samples were collected on the day be-
fore immunization and 2, 4, 6 weeks after immunization.
Evaluation of humoral responses
To measure T. gondii-specific IgG, plates (Dursley, UK)
were coated overnight with 10 μg/ml soluble tachyzoite
antigen in 0.1 M carbonate buffer pH 9.6 (50 μl per
well). After two hours’ blocking, sera diluted 1:200 in 1%
BSA–PBST20 (50 μl per well) were added and incubated
for 1 h at RT. After washing, bound antibodies were
detected by incubation at RT for 1 h with horseradish
peroxidase (HRP)-conjugated goat anti-mouse immuno-
globulins IgG, (Pharmingen, USA) at 1:1000 dilution in
1% BSA–PBST20 (50 μl per well). Peroxidase activity
was revealed by adding 50 μl per well of a solution con-
taining 12.5% H2O2, 0.1 M citrate-phosphate (pH 4) and
10 mg/ml of 3, 30, 5, 50- tetramethylbenzidine (TMB).
The reaction was stopped by adding 50 μl of 2 M H2SO4
and the optical density (OD) was read out at 492 nm in
an ELISA microplate reader (Bio-TEK, USA).
Lymphocyte proliferation assays
Three mice from each group were euthanized two weeks
after the last immunization. Their spleens were removedunder sterile conditions. Single-cell suspensions were
obtained by filtration through nylon mesh. After removal
of the erythrocytes, the remaining spleen cell suspensions
were adjusted to a final concentration of 5×106 cells/ml in
complete RPMI 1640 (Gibco-BRL) tissue culture medium.
Splenocyte suspensions (100 μL per well) were plated into
96-well U-bottomed tissue culture plates along with 100 μl
of stimulant diluted to appropriate concentrations in
complete RPMI 1640. The stimulant used was T. gondii
tachyzoite antigen at 50 μg/ml. Concanavalin A (10 μg/ml,
Sigma) was used as a positive control, and cells cultured
with media alone were used as negative controls. The
plates were incubated for three days in 5% CO2 at 37°C
and pulsed with 1 μ Ci [3H] thymidine per well for
the final 18 h. The cells were then harvested onto glass
fiber filters using a cell harvester (Skatron Instruments,
Norway). The radioactivity incorporated into the DNA was
determined by liquid scintillation.
Flow cytometry (FCM) of T lymphocyte subsets
Two weeks after immunization, the spleen cells were
isolated from immunized mice with RMPI 1640 medium
without serum. Cells adjusted to 1 × 106 with PBS were
stained with FITC-conjugated anti-mouse CD8+ mono-
clonal antibody (eBioscience, USA) and PE- conjugated
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T lymphocyte subsets were measured using flow cytometry
(Beckman Coulter, USA).
Cytokine assays
Splenocytes from immunized mice were cultured with
STAg as described for the lymphocyte proliferation assay.
At the end of the incubation period, the culture superna-
tants were harvested and centrifuged for 5 min at 110×g.
Commercial ELISA kits (mouse IFN-γ OptEIA, IL-4
OptEIA, Endogen, USA) were used according to the man-
ufacturer’s instructions to assay cytokine levels in culture
supernatants obtained at 24 h for IL-4 and 96 h for IFN-γ.
Challenge infection
Ten mice in each group were challenged intraperitone-
ally with 103 tachyzoite forms of T. gondii RH strain
4 weeks after the last immunization. The mice were ob-
served for 30 days and the time to death was recorded
where appropriate.
Statistical analysis
The statistical significance between different groups was
calculated with one-factor analysis of variance (ANOVA).
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Figure 2 The identification of recombinant plasmids and in vitro expr
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Marker 2000.Results
Plasmid construction and in vitro expression of
compound genes
The recombinant plasmids pSAG1, pSAG1/SAG3 and
pSAG1/SAG3-CTXA2/B with the correct insert orienta-
tion were detected by restriction enzyme analysis and
PCR. The sizes of SAG1, SAG3, CTXA2/B were 786bp,
492bp, 512bp respectively (Figure 2A).
pSAG1, pSAG1/SAG3 and pSAG1/SAG3-CTXA2/B
plasmids transfection bands were at 786bp, 1278bp,
1790bp respectively, which proved all the genes could be
expressed in HeLa cells. While there are only β-actin
gene bands in HeLa cells transfected by Liposome and
pcDNA3.1 (−) (Figure 2B).
Evaluation of humoral responses
BALB/c mice intramuscularly immunized with PBS,
pcDNA3.1 or pSAG1 resulted in none or only low anti-
T. gondii IgG titres in the serum of mice. In contrast,
much higher levels of anti-T. gondii IgG antibodies were
detected when mice were immunized with pSAG1/
SAG3 compared to pSAG1 (P<0.05). When CTXA2/B
genetic adjuvant was included, anti- T. gondii IgG values
increased markedly in the pSAG1/SAG3-CTXA2/B im-
munized group, which were significantly higher than












2   3   4  5   6  M2
ession of compound genes. A: Identification of recombinant
r 6000 Lane1. pSAG1 digested by EcoR I and BamH I; Lane2. pSAG1/
by EcoR I and Hind III; Lane 4. PCR product of SAG1; Lane 5. PCR
000. B: RT-PCR results of Hela cell transfected by recombinant plasmid.
pSAG1/SAG3, pSAG1/SAG3-CTXA2/B respectively; Lane M DNA
Table 1 Measurement of the cytokines in the immunized
mice by sandwich ELISA
Immunization regimen a Cytokine production (pg/ml) b SIc
IFN-γ IL-4
PBS 11±5 N.D 0.17
pcDNA3.1 13±4 N.D 0.32
pSAG1 24±6 N.D 1.38
pSAG1/SAG3 47±7 N.D 2.47
pSAG1/SAG3-CTXA2/B 89±10 N.D 4.28
a Mice were immunized by i.m. route on day 0 and day 14 and day 28 with
PBS, pcDNA3.1, pSAG1, pSAG1/SAG3, pSAG1/SAG3-CTXA2/B.
b The splenocytes taken from mice (n = 3, each group) 2 weeks after the last
immunization were examined for cytokine production by sandwich ELISA.
Values for IFN-γ from 96 h, values for IL-4 from 24 h.
N.D means not detectable.
c The results of proliferation assays are expressed as the stimulation index (SI),
calculated as the ratio between the mean counts per minute (cpm) for
triplicate stimulated cultures and the mean counts per minute for triplicate
unstimulated cultures. SI values 2.5-fold greater than the SI of the control
groups were considered as significant.
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immunized with or without CTXA2/B as a genetic adju-
vant (P<0.05) (Figure 3).
Cellular immune response analysis
Culture supernatants from antigen-stimulated splenocytes
were quantified with sandwich ELISA for Th1- and Th2-
type cytokines. Table 1 shows pSAG1, pSAG1/SAG3 and
pSAG1/SAG3-CTXA2/B immunization groups could in-
duce splenic T cells to secret high levels of IFN-γ compared
to control groups immunized with PBS and pcDNA3.1
(P<0.05). Double genes could induce splenic cell to secret
significant higher level IFN-γ production in immunized
mice than a single gene (P<0.05). Cultured splenocytes from
pSAG1/SAG3 and pSAG1/SAG3-CTXA2/B vaccinated
mice demonstrated a preferential production of IFN-γ on
stimulation with tachyzoite antigens, with little production
of IL-4, suggesting that the response was oriented to a Th1
type. Similarly, antigen-specific lymphocyte proliferation in
pSAG1/SAG3 immunization mice were higher than pSAG1
immunized mice (P<0.05). CTXA2/B as a genetic adjuvant
could effectively enhance the lymphocyte proliferation ac-
tivity in cultured splenocytes from pSAG1/SAG3-CTXA2/B
vaccinated mice (P<0.01).
To evaluate the change in T cell subsets after immu-
nization, we performed a phenotype analysis of murine
splenocytes. CD4+ and CD8+ T lymphocyte subsets from
the immunized mice were assayed by flow cytometry.
Table 2 shows the percentage of CD4+ and CD8+, and
the ratios of CD4+ and CD8+ T-cells. The percentage
of CD4+ T-cells in immunization group did not change
significantly compared to the control group. However,





















Figure 3 Kinetics and strength of humoral response in BALB/c
mice immunized with PBS, pcDNA3.1, pSAG1, pSAG1/SAG3,
pSAG1/SAG3-CTXA2/B. Mice were immunized on days 0, 14 and 28
and the tail vein serum samples were collected on the day before
immunization and 2, 4, 6 weeks after immunization.changed significantly. In mice immunized intramuscu-
larly with pSAG1, the percentage of CD8+ T cells is
26.37 ± 0.98, which is higher than the CD8+ T cells per-
centage in PBS group (18.67 ± 0.92), but not significant
different compared to empty plasmid pcDNA3.1 group. In
mice group immunized with pSAG1/SAG3 or pSAG1/
SAG3- CTXA2/B plasmid, the percentage of CD8
+ T cells
was 35.01 ± 0.88, 38.55 ± 0.94 and greatly increased com-
pared to other groups. Conversely, the ratios of CD4+ and
CD8+ T-cells decreased.Challenge study
Four weeks after immunization, mice were challenged
with 100 μl 1 × 103 RH strain tachyzoites of T. gondii in-
traperitoneally. Mice which were treated with PBS died
within 4 days. Mice immunized with empty plasmid intra-
muscularly died within 6 days. Mice immunized with
pSAG1 died within 8 days. While there was a 20% survival
rate for the mice immunized with pSAG1/SAG3 plasmid
intramuscularly. Furthermore, pSAG1/SAG3-CTXA2/BTable 2 CD4+ CD8+ subtype of T cells from immunization
mice were measured using flow cytometry
Immunization regimen a CD4+(%) b CD8+(%) b CD4+/CD8+
PBS 26.71±0.22 18.67±0.92 1.43±0.23
pcDNA3.1 27.62±0.25 24.71±0.85 1.12±0.29
pSAG1 26.45±0.34 26.37±0.98 1.00±0.35
pSAG1/SAG3 24.68±0.14 35.01±0.88 0.70±0.16
pSAG1/SAG3-CTXA2/B 25.15±0.23 38.55±0.94 0.65±0.24
a Mice were immunized by i.m. route on day 0 and day 14 and day 28 with
PBS, pcDNA3.1, pSAG1, pSAG1/SAG3, pSAG1/SAG3-CTXA2/B.
b The splenocytes culture supernatants taken from mice (n = 3, each group)
2 weeks after the last immunization were stained with FITC-labeled anti-mouse
CD8+ monoclonal antibody and PE-labeled anti-mouse CD4+ monoclonal
antibody, T lymphocyte subsets were measured using flow cytometry.
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mice survived (Figure 4).
Discussion
In this study, a DNA vaccine expressing two major sur-
face membrane antigens SAG1, SAG3 from T. gondii,
with or without the A2/B subunit of cholera toxin as a
genetic adjuvant was constructed. The immunity in-
duced by this vaccine in BALB/c mice and the protec-
tion afforded against challenge with the highly virulent
RH strain of T. gondii was evaluated.
Our results demonstrate that T. gondii surface mem-
brane antigens SAG1 and SAG3 genes, when used as a
multivalent DNA vaccine are capable of inducing a
stronger immune response than SAG1 single gene DNA
vaccine. Numerous studies have supported the role of
SAG1 in protection against T. gondii infection [20-22].
These studies show vaccination with SAG1 DNA could
induce specific humoral and cellular immune responses,
survival prolongation and brain cyst reduction. In an-
other study, a Glutathione-s-transferase (GST)-fused SAG3
of T. gondii (rSAG3) was used to immunize BALB/c mice
alone or in combination with Quil A (rSAG3/Quil A),
which resulted in partial protective immunity against T.
gondii infection through induction of a Th1-type immune
response [23].
In this study, a significant production of IgG anti-
bodies that recognize total T. gondii antigen was induced
in mice immunized with pSAG1/SAG3 compared with
mice immunized with pSAG1 (P<0.01). Similarly, antigen-
specific lymphocyte proliferation of splenocytes from mice
in the pSAG1/SAG3 immunization group were higher than
pSAG1 immunization group (P<0.05). Also the double gene















Figure 4 Survival rates of immunized mice after challenging with RH
pcDNA3.1 (▲), pSAG1(Δ), pSAG1/SAG3(□), pSAG1/SAG3-CTXA2/B (■) three
(10 per group) were administered by challenging intraperitoneally with 1 xproduction compared to the single gene group. Further-
more, a high level of protection was achieved in the double
gene group. The mice immunized with pSAG1/SAG3 not
only showed extended survive times but maintained a 20%
survival rate after challenge with 103 RH tachyzoites, while
all the pSAG1 immunization group died within eight days
after challenge. Thus indicates that multi-antigenic DNA
vaccines provide better protection against toxoplasmosis
and are superior to a single-antigen DNA vaccine.
Further, in order to enhance the immunogenicity of
the vaccine, the multivalent antigen gene was connected
to the A2/B subunit of cholera toxin. CTXA2/B, A2/B
subunit of a cholera toxin, has been demonstrated to be
an effective adjuvant in our previous study [24,25]. In
this study, CTXA2/B was linked to the double gene
vaccine construct as a genetic adjuvant. As expected,
stronger immune responses were induced by this vac-
cine in BALB/c mice and even high levels of protection
were afforded against challenge with the highly virulent
RH strain. Enhanced IgG antibodies were observed in
pSAG1/SAG3-CTXA2/B immunization group in week 4
and week 6. For the cellular immune response the dif-
ference was significant (P<0.05) between groups with
and without CTXA2/B gene. CTXA2/B gene adjuvant
greatly improves the secretion of IFN-γ and lymphocyte
proliferation activity, especially in the pSAG1/SAG3-
CTXA2/B immunization group to maintain a 40% sur-
vival rate after challenge with 103 RH tachyzoites.
CD4+ and CD8+ T-cell subsets play a central role in
the establishment of protective immunity in the host
and are largely involved in the protection provided by
vaccines [26,27]. CD8+ T-cell is a major cellular T cell
subset involved in acquired immune protection against







tachyzoites of T. gondii. BALB/c mice were immunized with PBS(● ),
times with two weeks interval. Four weeks after final inoculation, mice
103 tachyzoites of T. gondii RH strain.
Cong et al. Parasites & Vectors 2013, 6:63 Page 7 of 8
http://www.parasitesandvectors.com/content/6/1/63lymphocytes subsets percentage in the pSAG1/SAG3
and pSAG1/SAG3-CTXA2/B immunization mice group,
with the ratio of CD4+ T-cells and CD8+ T-cell in mono-
nuclear cells showing significant differences compared to
the control and pSAG1 immunization mice. Both T-cell
subsets are important sources of IFN-γ, more optimum
protective CD8+ T cell responses depend on the ability of
CD4+ T-cells to provide the growth factor IL-2 [28,29].
Herein, compared with multivalent DNA vaccine immu-
nization, introduction of CTXA2/B further enhanced the
Th1 cell-mediated immunity with higher levels of IFN-γ
but low levels of IL-4. These results clearly demonstrate
that CTXA2/B can significantly augment Th1-type cellular
immune responses in BALB/c mice.
In order to evaluate of protection potency, highly viru-
lent RH strain of T. gondii was used for the challenge
study. No effective vaccine has been shown to com-
pletely protect against intraperitoneal challenge with the
RH strain of T. gondii [30,31]. In our study, when chal-
lenged with lethal doses of T. gondii (1×103), all control
mice (PBS and empty plasmid group) died within 6 days.
Low protection against RH strain challenge was observed
in pSAG1 immunization group. While there was a 20%
survival rate for the mice immunized with pSAG1/SAG3
plasmid intramuscularly. Furthermore, pSAG1/SAG3-
CTXA2/B vaccinated mice not only survived longer but
showed a 40% survival rate. For the evidence for the differ-
ential expression of miRNAs in the two genetically distinct
strains, RH and ME49, of T. gondii has been identified
and defined [32]. The efficacy of this compound DNA vac-
cine evaluated by comparison of the brain tissue cyst bur-
den in vaccinated and control groups, using a moderately
virulent T. gondii strain, ME49, might be performed in the
future [33].
Conclusions
Multi-component DNA vaccine encoding T. gondii anti-
gens SAG1, SAG3 with the adjuvant CTXA2/B gene
could enhance the humoral and cellular immune re-
sponse accompanied by a significant increase in survival
rates in vaccinated mice. CTXA2/B as a genetic adjuvant
could enhance humoral and cellular immunity of DNA
vaccines. This compound DNA vaccine is a promising
candidate to protect animals and humans against Toxo-
plasma gondii.
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